Inhibikase Therapeutics
IKT
12 hedge funds and large institutions have $1.02M invested in Inhibikase Therapeutics in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 4 closing their positions.
130% more capital invested
Capital invested by funds: $444K → $1.02M (+$577K)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
8.27% more ownership
Funds ownership: 3.32% → 11.59% (+8.3%)
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.02M |
| 2 |
William Blair & Company
Chicago,
Illinois
|
+$68.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$65.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$48.9K |
| 2 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
-$42.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$6.94K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$4.32K |
| 5 |
Renaissance Technologies
New York
|
-$1.03K |
IKT Hedge Fund Activity: Q2 2024 in Review
12 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q2 2024, worth a combined $1.02M — up 130% from $444K a quarter earlier.
Fund positioning in IKT was balanced in Q2 2024: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 2 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.02M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $48.9K sold.
- 12 institutional investors held Inhibikase Therapeutics (IKT) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $1.02M of Inhibikase Therapeutics stock for Q2 2024, up 130% quarter-over-quarter.
- 4 funds opened new Inhibikase Therapeutics positions in Q2 2024 and 4 closed out, a net change of 0 holders.
- The largest Inhibikase Therapeutics buyer in Q2 2024 was Armistice Capital, an estimated $1.02M added.
- The largest Inhibikase Therapeutics seller in Q2 2024 was Susquehanna International Group, an estimated $48.9K sold.
Based on aggregated 13F filings for Q2 2024.